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1. Introduction
Head and neck cancer is the sixth most common cancer worldwide and one of the most ag‐
gressive malignancies in human population. The most common histologic type among the
head and neck tumors are the squamous cell carcinomas (SCC). Despite the significant ef‐
forts committed during the last decades in its early detection, prevention and treatment,
head and neck cancer prognosis remains very poor with the rising incidence in developed
countries and younger population. Carcinogenesis of Head and Neck Squamous Cell Carci‐
noma (HNSCC) is a multistep process, which arises through an accumulation of genetic and
epigenetic alterations. Although the impact of genetic changes in oral carcinogenesis is well-
known, over the last decade it has been demonstrated that epigenetic changes, especially
aberrant DNA methylation, play a significant role in HNSCC.
1.1. Head and neck cancer – Etiology and risk factors
Head and Neck Squamous Cell Carcinoma is the sixth most common cancer in males and
tenth in females worldwide [1]. Despite the fact that significant results have been achieved
during the last decades in its early detection, prevention and treatment, the survival rate has
remained less than 40%, and HNSCC remains one of the most aggressive malignancies. Fur‐
thermore, the incidence of this carcinoma is rising in developed countries and younger pop‐
ulation, particularly young women [2, 3]. Early stages of the disease are associated with
minimal symptoms, thus small percentage of HNSCC has been diagnosed at an early clinical
stage. Advanced stages respond poorly to current cancer therapies, with high incidence of
local and regional relapse and lymph node metastasis [2, 4, 5].
© 2013 Magić et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Head and neck cancers include malignancies arising from different anatomical sites within
the upper aero-digestive tract. Head and neck cancers are characterized by heterogeneous
histology. The majority carcinomas that arise from squamous cell epithelia are head and
neck squamous cell carcinomas (HNSCC), while other cancer types that can occur in the
head and neck include thyroid cancer, malignant salivary gland tumors, lymphomas and
sarcomas. HNSCC include cancers of the oral cavity, larynx, pharynx (oropharynx, hypo‐
pharynx, nasopharynx), and esophagus, [4, 5], Figure 1.
1.2. Risk factors for HNSCC
Both environmental and genetic factors play an important role in the etiology of head and
neck cancers but the causal relationship between environmental factors, lifestyle and tumor
development is not yet fully elucidated. The mucosa of the upper aerodigestive tract is ex‐
posed to number of carcinogens attributed to cause genetic and epigenetic changes that ulti‐
mately lead to head and neck cancer development. HNSCC incidence is influenced by age,
genetic factors, geographic region and different lifestyle factors, including alcohol, smoking,
betel quid use, oral hygiene, and Human Papilloma Virus (HPV) infection [5]. Emerging evi‐
dences are indicating that environmental factors, such as smoking, alcohol and diet could
directly or indirectly affect epigenetic mechanisms of gene expression regulation and DNA
methylation in HNSCC.
1.3. Tobacco and alcohol use in HNSCC
Smoking and alcohol consumption are the major risk factors for head and neck cancers [6,
7]. In addition, the combination of both alcohol and tobacco use synergically increases the
risk for HNSCCdevelopment more than 10 times [8]. Cigarette smoking is the major cause of
lung cancer and is associated with head and neck, esophagus, bladder, breast and kidney
cancer [9]. Increased risk with smoking may be due to the direct effect of tobacco carcino‐
gens or due to genetic polymorphisms in enzymes that activate or detoxify carcinogens.
Several carcinogens present in cigarette smoke are inactivated by a family of enzymes cyto‐
chrome P-450 (CYP), which convert carcinogens into reactivated intermediates. These inter‐
mediates form DNA adducts that need to be detoxified by a number of enzymes, including
glutathione S-transferase [GST) [10]. Single nucleotide polymorphisms (SNPs) in these genes
could be an alternative mechanism that modulates the effects of cigarette smoke. Even
though alcohol and smoking are known risk factors, only a fraction of smokers and alcohol
consumers develop HNSCC, suggesting that genetic susceptibility and interactions between
genetic, epigenetic and environmental factors could play an important role in the etiology of
HNSCC [11, 12].
Alcohol consumption has been associated with an increased risk of the head and neck,
esophagus, liver, colorectal, and breast cancer [13]. Possible mechanisms by which alcohol
exerts its harmful effect includes the genotoxic effect of ethanol metabolite acetaldehyde,
production of reactive oxygen- and nitrogen species, changes in folate metabolism, genera‐
tion of DNA adducts and inhibition of DNA repair. Also, alcohol could exert its damaging
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effect directly, either acting as a solvent of carcinogens from tobacco smoke or damaging the
oral mucosa, that enhances the penetration of carcinogens from tobacco smoke [7]. Genetic
polymorphisms of ethanol-metabolizing enzymes, including alcohol dehydrogenases
(ADH) (which metabolizes alcohol into acetaldehyde), with a different ability to generate
carcinogen acetaldehyde, may determine individual susceptibility to head and neck cancer.
Acetaldehyde can form adducts with DNA, interfering with DNA synthesis and repair [7,
13]. “Fast-metabolizing” ADHs genotype was associated with the increase of OSCC and
HNSCC risk [14, 15, 16]. By the contrast, in other studies “fast-metabolizing” ADHs geno‐
type was found to be associated with decreased risk of HNSCC [11, 17, 18]. Therefore, the
mechanism by which smoking and alcohol causes increased risk for HNSCC and the role of
alcohol and tobacco-related polymorphisms have not been fully elucidated.
Figure 1. Diverse anatomical localization of Head and Neck Squamous Cell Carcinomas. Although head and neck can‐
cers are characterized by heterogeneous histology, the majority carcinomas arise from squamous cell epithelia of the
oral cavity (tongue, buccal mucosa, floor of the mouth), oropharynx (soft palate, base of tongue, tonsils), hypophar‐
ynx, nasopharynx, larynx (supraglotis, glottis, subglotis) and esophagus.
1.4. HPV infection in HNSCC
In addition to alcohol and tobacco exposure, human papilloma virus (HPV) infection has al‐
so a significant part in the etiology of head and neck cancer. HPV cancers predominantly
arise from tongue and palatine tonsils within the oropharynx [5, 19]. Acting in synergy with
tobacco use and heavy alcohol consumption, HPV infection with high-risk types is consid‐
ered as an etiological factor in the development of HSCC and OSCC [5]. Reported incidence
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of high-risk HPVs in oral carcinoma patients varied from 0% to 100% [20], depending on the
methods used for HPV detection, tumor-host characteristics of the examined group of pa‐
tients, varying numbers of included tissue samples, but it is also affected with different dis‐
tribution of oncogenic HPVs in different world regions. The DNA of oncogenic HPVs is
present in 20% of all HNSSCs and in nearly 60% of tonsillar cancers [5, 8]. There is increasing
evidence that HPV-associated HNSCC carcinomas are distinct clinical and pathological tu‐
mor entity from alcohol and smoking-associated HNSCCs with regards to risk factors, tumor
biology and progression [5]. Infection with oncogenic HPV types, predominantly HPV16
and HPV18 is associated with increased risk of HNSSC [5, 19].
HPV infection causes deregulation of cell cycle and apoptosis by inactivation of Rb and p53 tu‐
mor suppressor gene protein products, involved in the maintenance of genome stability. E6
protein of high risk HPVs affects the p53 protein function by ubiquitin-dependent degrada‐
tion. Although p53 tumor suppressor gene is the most often mutated gene in human oncology,
in tumors with HPV etiology is not clear in which extent the mechanism of p53 mutation is in‐
cluded in p53 inactivation. It can be assumed that p53 mutations occur most frequently in HPV
negative than in the HPV positive head and neck cancers, but it is questionable if the presence
of p53 mutation in HPV infected tumors additionally influences prognosis of the patients. Nu‐
merous studies with conflicting results deal with the influence of oncogenic HPV types and
prognosis of HSCC. The majority of them reported that HSCC patients with HPV infection
have better prognosis than the patients who are HPV negative [5, 21, 22]. On the contrary, our
previous results concerning OSCC patients in stage III of the disease showed worse overall and
disease-free survival for patients infected with high-risk HPV types (HPV 16, 18 and 31) [23],
indicating the presence of more aggressive disease in these patients. Our study comparing dis‐
ease-free interval (DFI) and overall survival (OS) between patients with HPV infection only
and the patients with HPV infection and p53 mutation showed significantly shorter disease-
free interval as well as overall survival in patients with both HPV infection and p53 mutation.
Presence of p53 mutations in HPV infected tumors confer a higher risk of recurrence in this dis‐
ease. In addition, since all patients were treated with postoperative radiotherapy, shorter DFI
indicate that the response to radiotherapy may be influenced by p53 status [24]. However, it
has been recently reported that it is unlikely that HPV infection plays significant role in mobile
tongue carcinogenesis in young OSCC patients [25].
The role of HPV infection in the etiology, as well as in prognosis of head and neck cancers
varies and it depends on head and neck cancer subtypes and different anatomic site of tu‐
mors. From that point of view, it is clear that HPV typing, together with other molecular
markers may help in defining a particular group of tumors in regard to prognosis and re‐
sponse to anti cancer therapies.
1.5. Diet and HNSCC
Recent studies provide growing evidence that some dietary components, might affect the
process of carcinogenesis. There is a growing body of evidence that bioactive food compo‐
nents, such as isothiocyanates from cruciferous vegetables (cauliflower, cabbage, and broc‐
coli), diallyl sulfide (an organosulphur compound from garlic), green tea flavonoids, folate,
and selenium, effect on cancer might be mediated through epigenetic mechanisms. Several
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recent studies indicate that dietary habits and fruit and vegetable intake could be associated
with cancer risk [26, 27]. Increased fruit and vegetable consumption was recently associated
with reduced occurrence of HNSCC [28]. However, the findings of association of diet and
cancer risk are still confounding.
Figure 2. Schematic presentation of synergistic effect of different genetic alterations in transformation of normal to
malignant cell. Gene mutations can be inherited (BRCA1, BRCA2, RET, VHL, APC) and associated with a predisposition
to certain cancer or cancer syndromes. Also, mutations can be acquired leading to the strong predisposition to malig‐
nant transformation of cells (K-ras, p53, HER2, bcr-abl, bcl-2, Rb). The human genome is characterized with enormous
number of genetic polymorphisms that sometimes results with impaired function of the gene product, especially
when cells are exposed to environmental or host risk factors. Hypermethylation of gene promoter sequences causes
gene silencing that is of great importance for tumor suppressor genes. All these genetic alterations can impair func‐
tion of other genes and further contribute to increased risk of malignant transformation.
2. Molecular changes In HNSCC
Second half of 20th century and beginning of 21st century are marked with almost revolution‐
ary breakthrough in our understanding of human gene structure and functions. The rapid
development of biotechniques led to the sequencing of complete human genome and later of
genome and transcriptome of many human tumors [29, 30]. Even before these achievements,
it was well accepted that malignant tumors, on the molecular level, are disease of genes.
This knowledge led to enormous number of worldwide research projects and publications
concerning association of gene alterations in tumor cells with cancerogenesis and early diag‐
nosis, tumor progression, tumor staging and response to therapy. In spite of many practical/
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clinical results of these studies [Her-2/neu, BRCA-1 and BRCA-2 in Breast Cancer; K-ras and
EGFR in Colon Cancer; bcr-abl in Chronic Myeloid Leukemia; B-RAF and c-KIT in Melano‐
ma; detection of dominant clone of B- and T-lymphocytes in tracking minimal residual dis‐
ease in lymphomas and leukemia’s [29-33], still much more questions concerning
significance of gene alterations for tumor development and treatment remains unanswered.
In the last 10-15 years significant efforts are done to fulfill these gaps in our understanding
of molecular pathogenesis of cancer by studying epigenetic changes of tumor tissues.
These alterations are of special interest because epigenetic changes are tumor/tissue specific,
although inheritable epigenetic alterations are under strong influence of environmental risk
factors and patient behavior and they are potentially reversible. Intensive research of epige‐
netic alterations in human tumors and their association with environmental risk factors and
patient behavior put an attention to another group of gene alterations, i.e. on inherited gene
polymorphisms. These researches tried to elucidate connection of certain gene polymor‐
phisms with environmental and host risk factors and epigenetic alterations in different hu‐
man tumors and in HNSCC [12, 16, 34-36], Figure 2.
Carcinogenesis of HNSCC is a multistep process, which arises through an accumulation of
genetic and epigenetic alterations. These genetic alterations result in inactivation of multiple
tumor suppressor genes and activation of proto-oncogenes by deletions, point mutations,
promoter methylation, and gene amplification [3], Table 1.
Genetic changes Locus / gene Cancer type Frequency Ref.
LOH
9p21-22/ p16INK4a/p14ARF HNSCCOSCC 70–80% 37, 38,39, 40
3p/ RASSF1A, FHIT, RARB2 OSCCHNSCC 30–70% 37, 39, 40, 47
17p13/p53 HNSCC 76% 39
11q OSCC 20-33% 37
13q14/Rb HNSCC 68% 39
8p OSCC 53-83% 37
Mutation
9p21-22/ p16 OSCC 70% 41
5q21-22/APC OSCC 50% 37
17p13/p53 HNSCC 40-79% 49
11p15/H-ras OSCC 35-55% 37
Amplification
11q13/(PRAD-1/Cyclin D1/hst-1/int-2) HNSCC 30–50% 46, 47
7p12/EGFR OSCC 30% 53, 54
Table 1. Frequent genetic abnormalities in head and neck cancer.
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Genetic instability in regions leads to loss of chromosomal region that contains tumor suppres‐
sor genes. A high incidence of Loss of heterozygosity (LOH) observed at 9p, 8p, 3p, 9q, and 11q
regions were associated with tumor stage, and poor histological differentiation in HNSCC [37].
Loss of heterozygosity (LOH) of 9p21 appears is an early and frequent event in head and neck
carcinogenesis [37, 38-40]. The CDKN2A gene locus found in 9p21 region encodes two differ‐
ent transcripts, p16 and p14ARF, which are responsible for G1 cell cycle regulation and MDM2
mediated degradation of p53. P16 and p14 are often inactivated in HNSCC through homozy‐
gous deletion, by promoter methylation, and by point mutations [41-44].
Loss of chromosome region 3p is a common early genetic event in HNSCC [2, 40, 45]. Genet‐
ic alterations at 3p that are common in HNSCC and OSCC contains tumor suppressor genes
Fragile histidine triad (FHIT) gene mapped at 3p14, Ras association family (RASSF1A) gene,
mapped at 3p21, and Retinoic acid receptor B2 gene (RARB2), mapped to chromosome re‐
gion 3p24 [37, 40]. Amplification of 11q13 leads to overexpression of cyclin D1 [46], detected
in 30–60% of HNSCC and 40% of cases of oral squamous dysplasia [47].
There has been much research on the tumor suppressor gene p53 and its role in HNSCC and
OSCC carcinogenesis. The p53 protein blocks cell division at the G1 to S boundary, stimu‐
lates DNA repair after DNA damage, and induces apoptosis. P53 has been shown to be
functionally inactivated in oral and head and neck tumors [48]. LOH of 17p13, which con‐
tains p53 and point mutations of the p53 are seen in more than 50% of HNSCC cases [39, 49].
Cigarette smoking has been associated with the mutation of p53 in head and neck cancers
[14]. Investigations about the prognostic value of p53 status in head and neck cancer sub‐
types hardly can get a clear result due to the presence of large heterogeneity in regard to
patients characteristics, and methods for p53 detection. Meta-analysis of Tandon et al [50]
pointed out that evidence about the prognostic value of p53 in head and neck cancer squa‐
mous cell carcinomas has been inconclusive. However, determination of p53 status of
HNSCC may be of particular interests due to its possible role in prediction of the response to
cisplatin based chemotherapy. Cisplatin chemotherapy is widely used chemotherapeutical
approach in the treatment of head and neck cancers and data that patients with p53 muta‐
tions respond better to cisplatin chemotherapy need further confirmation [51]. Chemothera‐
py responses in HNSCC patients is also influenced by polymorphism at codon 72 of p53
gene. In patients with wild type p53, arginine at codon 72 is associated with better response
to chemotherapy. On the contrary, if p53 is mutated, proline at position 72 is better option
[52]. Better understanding of cellular processes and their actors such as p53 network and
their relation to clinical settings will help in appropriate biomarker characterization. Epider‐
mal growth factor receptor (EGFR) is overexpressed in 90% of HNSCC [53], often due to am‐
plification [54]. Thus, frequent molecular abnormalities in head and neck squamous cell
carcinoma include alterations in tumor suppressor genes p16INK4A, p53, p14ARF, FHIT,
RASSF1A, Rb, cyclin D1, and activation of oncogenes, such as members of the ras gene fami‐
ly, c-myc, and EGFR [2-4], Table 1.
A large number of previous studies have also suggested the correlation between polymor‐
phisms of genes involved in cell cycle control, angiogenesis and metabolism of alcohol and
carcinogens and susceptibility to head and neck cancer [10, 16, 34-36].
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Although the impact of genetic changes in oral carcinogenesis is well-known, over the last
decade it has been demonstrated that epigenetic changes, especially aberrant DNA methyla‐
tion, play a significant role in HNSCC [55]. Epigenetic modifications are heritable changes in
gene expression that are not coded in the DNA sequence [56]. These changes are mitoticaly
(clonally) heritable and potentially reversible, which provides large possibilities of epigenet‐
ic therapy. Additionally, epigenetic changes could be modulated by the nutrition, environ‐
mental and genetic factors and/or gene-by-environment interactions. Main mechanisms of
epigenetic control in mammals include DNA methylation, histone modifications and RNA
interference (RNA silencing).
3. DNA methylation
DNA  methylation  of  cytosine  in  a  CpG  dinucleotide  is  the  key  epigenetic  modifica‐
tion  in  mammals.  The  covalent  addition  of  a  methyl  group  to  the  5-carbon  (C5)  po‐
sition  of  cytosine  that  are  located  5'  to  a  guanosine  base  in  a  CpG  dinucleotide  are
catalyzed  by  a  family  of  enzymes  DNA  methyltransferases  (DNMTs).  CpG  dinucleoti‐
des  are  asymmetrically  distributed  in  the  genome.  Throughout  the  genome  rare  soli‐
tary  CpGs  are  heavily  methylated.  In  contrast,  CpG  clustered  in  small  stretches  of
DNA  (0.5-4kb  regions),  with  greater  than  50%  GC  content,  are  termed  ‘CpG  is‐
lands’.  Of  approximately  50%  the  genes  in  the  genome  CpG  islands  are  associated
with  promoter  regions.  In  normal  cells,  most  CpG  sites  outside  of  CpG  islands  are
methylated,  whereas  CpG  islands  in  gene  promoters  are  usually  unmethylated,  inde‐
pendently  of  the  gene  transcription  status  [56].  During  the  process  of  cancerogenesis
paradoxical  changes in  DNA methylation patterns  occurs,  with simultaneous global  hy‐
pomethylation  and  regional  hypermethylation  changes.  Global  DNA  hypomethylation
may  activate,  ‘unlock’  repetitive  elements  that  could  affect  genome  stability  or  could
lead to  transcriptional  activation of  latent  viruses  or  oncogenes.  Simultaneously,  region‐
al  hypermethylation  leads  to  transcriptional  silencing  of  tumor  suppressor  genes.  Cy‐
tosine  methylation  of  CpG  islands  in  the  promoters  of  tumor  suppressor  genes  causes
their  inactivation,  transcriptional  silencing  and  consequently  malignant  transforma‐
tion.  Investigations  showed  that  the  number  of  cancer-related  genes  that  are  inactivat‐
ed by epigenetic  modifications  equals  or  even exceeds the  number  of  genes  inactivated
by mutation.  Furthermore,  genetic  and epigenetic  changes  have almost  identical  biolog‐
ical  effect  and  pattern  of  gene  expression  [56].  Pattern  of  tumor  suppressor  genes  hy‐
permethylation  shows  tumor-type  specificity.
While DNMT3A and DNMT3B are mostly involved in de novo methylation, DNMT1 is in‐
volved in the maintenance of DNA methylation after replication [56]. Several studies have
shown DNMT overexpression (mainly DNMT1 and DNMT3B) in cancer, including HNSCC
[57]. The analysis of DNMT knockout cells revealed that individual enzymes also interact
between each other, and interact with other chromatin modifying enzymes, histone deacety‐
lases (HDAC) and methyl-CpG binding proteins (MBPs). Methylation of cytosine within
CpG islands is associated with binding of MBPs, which recruit HDAC to methylated DNA in
regions of transcriptional silencing. Histone deacetylation, catalyzed by HDACs, leads to the
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chromatin condensation and suppression of DNA transcription. Thus, DNA methylation
and histone modifications are not isolated events, but highly coordinated [56].
3.1. DNA methylation in HNSCC
Frequent hypermethylation of tumor-related genes were observed in cancer tissue of OSCC
and HNSCC, in the normal adjacent mucous in the OSCC [58], dysplastic tissue [59], and leu‐
koplakia [60]. Promoter hypermethylation can also be detected in buccal swabs samples of
tobacco and alcohol users [58], Thus, DNA methylation has been considered as an early
event in head and neck carcinogenesis.
The list of genes that are found to be inactivated by DNA methylation events in HNSCC is
growing rapidly and includes genes involved in the cell cycle control (p14, p15, p16 and
p53), DNA damage repair (MGMT, hMLH1, and ATM), apoptosis (DAPK, RASSF1A, and
RARβ), Wnt signalling (APC, RUNX3, WIF1, E-cad and DCC) SFRP family genes, TCF21, etc.
[42, 44, 55, 58-62], Table 2.
FUNCTION Gene Gene name Locus Gene Action HNSCCmethylation Ref.
Cell Cycle
Control
p16
Cyclin-dependent
kinase inhibitor
2A (CDKN2A)
9p21 Regulation ofthe Rb pathway 10-70% 42, 96
p15 Cyclin-dependentkinase inhibitor 2B 9p21
TGF beta-mediated
cell cycle arrest 23-80% 151
Apoptosis
p14
Alternative open
reading frame (ARF)
of INK4a locus
9p21 Pro-apoptosis 18-46% 75-77, 96
DAPK1 Death-associatedprotein kinase 1 19q34
p53-dependent
apoptosis 18-77%
42, 44, 61,
68, 72, 78
Wnt signaling
pathway
APC Adenomatouspolyposis coli
5q21-
22
Wnt signaling
and adhesion 20-68% 44, 92-95
CDH1 E-cadherin 16q22 Cell–cell adhesion 2-66% 44, 72, 81-88
SFRP
Soluble frizzled
receptor protein
genes family
10q24 Antagonists ofthe Wnt pathway 30-94% 97-99
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FUNCTION Gene Gene name Locus Gene Action HNSCCmethylation Ref.
WIF1 Wnt inhibitoryfactor 1 12q14
Secreted Wnt
antagonist 25-90% 62, 97, 102
RUNX3 Runt-relatedtranscription factor 3 1p36
Wnt signaling
inhibitor, TGF-β-
induced
tumor suppression
18-36% 62, 99-101
DNA damage
repair
hMLH1 human mutL homolog 1 3p21 DNA mismatch repair 8-76% 96, 106, 107
MGMT O
6-mehylguanine
DNA methyltransferase 10q26
DNA repair
for alkylated guanine 10-57%
59, 44, 72,
103-105
Tumor
suppressor
FHIT Fragile Histidine Triad 3p14 Control of cell cycle 33-84% 96, 110
RASSF1A
Ras association
(RalGDS/AF-6)
domain family
member 1A
3p21
RAS pathway
regulation and
tumor suppression
10-76% 45, 72, 78,79, 96
DCC Deleted inColorectal Cancer 18q21 Cell–cell adhesion 17-75% 108, 109
RARβ Retinoic acidreceptor beta 3p24
Regulatory protein
and apoptosis 53-88% 59, 78
Table 2. Genes commonly methylated in HNSCC.
3.2. DNA methylation association with progression and prognosis in HNSCC
A number of tumor suppressor genes hypermethylation has been associated with worse
outcome in various cancer types. Hypermethylation of the p16  and WIF1  genes [63] and
RASSF1A  and  RUNX3  methylation  status  [64]  were  found to  be  independent  prognos‐
tic factors non-small cell  lung cancers. DAPK  promoter hypermethylation has been asso‐
ciated  with  tumor  aggressiveness  and  poor  prognosis  in  lung  cancer  [65].  E-cadherin
promoter  hypermethylation  was  found  to  be  the  prognostic  factor  of  worse  prognosis
in  diffuse  gastric  cancer  [66],  and  in  non-small  cell  lung  carcinoma [67].  Epigenetic  in‐
activation  of  several  genes  by  DNA  methylation  has  been  found  to  associate  with
HNSCC  progression  [44,  58,  61,  68].
p16INK4a is cyclin-dependent kinase inhibitor which regulates the Rb pathway, leading to in‐
hibition of cell cycle progression. An alternate spliced product of the same INK4a locus is
another tumor suppressor gene p14ARF (Alternative open reading frame). Loss of p16 in
head and neck and oral tumors has been frequently reported [69, 70]. p16 methylation was
correlated with malignant transformation of oral epithelial dysplasia and is a potential bio‐
marker for prediction of prognosis of mild or moderate oral epithelial dysplasia, with the
overall sensitivity and specificity of >60% [71]. Previously, p16 methylation status has been
correlated with tumor stage, lymph node metastasis and tumor size in HNSCC [72], and
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poorly differentiated HNSCC [73]. p16 hypermethylation has been associated with poor
prognosis in HNSCC [55, 74] and OSCC [75]. Interestingly, p16INK4A and p14ARF genes,
transcribed from the same locus INK4A by alternate splicing, could have a diametrically op‐
posite clinical effect in oral cancer patients when methylated. Promoter methylation of p16
was associated with increased disease recurrences and worse prognosis, whereas p14 meth‐
ylation was strongly associated with lower disease recurrence and was found to be a good
prognostic predictor for oral carcinoma [75]. However, other studies associated p14 methyla‐
tion with tumor stage and lymph node involvement of OSCC [76] and poor prognosis [77].
These findings indicate that DNA methylation status of INK4A/ARF locus could be used as a
prognostic biomarker for assessing the aggressiveness of disease in oral and head and neck
carcinoma patients.
Death  associated  protein-kinase  (DAPK),  plays  a  critical  role  in  apoptosis  regulation in  tu‐
mor  development,  and  commonly  is  hypermethylated  in  HNSCC  [42]  and  OSCC  [68].
DAPK  promoter  methylation showed the positive  correlation with lymph node involve‐
ment [42, 72, 78] and advanced disease stage in HNSCC  [42, 72].  The presence of DAPK
promoter  hypermethylation  detected  in  surgical  margins  was  associated  with  the  de‐
creased overall survival and was shown to be an independent prognostic factor for over‐
all  survival  in  OSCC  patients  [61].
RASSF1A Ras association (RalGDS/AF-6) domain family member 1A, involved in RAS path‐
way regulation and tumor suppression, is frequently inactivated by promoter hypermethy‐
lation in HNSCC [45, 72]. RASSF1A methylation correlates with head and neck tumor stage
[72], poor disease-free survival of OSCC [79] and lymph node metastasis in nasophageal car‐
cinomas [78].
E-cadherin (E-cad) has a dual role in a mammalian cell, as a Ca+2-dependent cell adhesion
molecule, and as a part of the complex signaling Wnt pathway interacting with β- and α-
catenine [80]. Hypermethylation of E-cad is a common event in HNSCC [44, 72, 81, 82]. Re‐
duced E-cad expression as a consequence of promoter hypermethylation leads to the
development of the invasive phenotype in the OSCC [83], and is associated with lymph
node metastasis in the OSCC [84] and HNSCC [85]. Hypermethylation of E-cad has previous‐
ly been associated with tumor stage of HNSCC [72] and nasopharyngeal carcinomas [86]
and lymph node metastasis of oral [82] and nasopharyngeal carcinomas [87]. Down-regula‐
tion of CDH1 due to hypermethylation contributed to the progression of esophageal cancer
[88], led to poor differentiation and the development of the invasive phenotype in the OSCC
[83], and salivary gland carcinomas [89]. Furthermore, E-cad hypermethylation was associat‐
ed with poor survival in the OSCC [84] and HNSCC [85]. Recently published investigations
showed that E-cad gene hypermethylation was associated with the decreased survival in
HNSCC patients [90]. In addition, advanced OSCC patients with E-cad promoter methylation
had significantly worse 3- and 5-year survival rates [44], and E-cad hypermethylation was
found to be an independent prognostic factor in oral tongue carcinoma [81]. However,
HNSCC patients with E-cad promoter methylation had lower rates of local recurrences and
better disease-specific survival and outcome [91], which indicates that the role of E-cad gene
methylation in head and neck carcinomas has not been fully elucidated.
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APC gene plays an integral role in the Wnt signaling pathway in binding and degrading of
β-catenine. Hypermethylation of the APC gene promoter is frequent in HNSCC [92-94], and
OSCC [44]. APC methylation status has previously been associated with worse prognosis of
esophageal carcinoma [95]. However, in another study on esophageal cancer, hypermethyla‐
tion of the APC gene was related to a lower number of metastatic lymph nodes and better
recurrence rates [96].
SFRP (soluble frizzled receptor protein) family genes are involved in the inhibition of Wnt
signaling. Promoters of SFRP-2, SFRP-4, SFRP-5 genes showed methylation in OSCC, where‐
as SFRP-1 was demethylated in oral cancer [97]. SFRP-1 has been associated with tumor
grade in OSCC [98]. Hypermethylation of SFRP-1 was associated with an increased risk of
esophageal cancer recurrence [99].
RUNX3 Runt-related transcription factor 3 gene plays a role in the transforming growth fac‐
tor-beta (TGF-β) -induced tumor suppression pathway. RUNX3 may have an oncogenic role
in HNSCC and its expression may predict malignant behavior [100]. In contrast to HNSCC,
in OSCC the RUNX3 gene is downregulated due to promoter hypermethylation [101] and
associated with lymph node involvement and tumor stage in tongue carcinomas [62]. Hy‐
permethylation of RUNX3 detected in the plasma of esophageal cancer patients was signifi‐
cantly associated with an increased risk of cancer recurrence [99].
WIF1 Wnt inhibitory factor 1, gene involved in the inhibition of Wnt signaling, is commonly
methylated in the HNSCC [102] and OSCC [62, 97]. Its methylation status was correlated
with lymph node metastasis in nasopharyngeal carcinoma [102].
MGMT O(6)-methylguanine-DNAmethyltransferase a DNA repair gene that removes muta‐
genic O6-guanine adducts from DNA, is inactivated by hypermethylation in HNSCC [59]
and OSCC [44]. MGMT promoter hypermethylation was associated with tumor stage of
HNSCC [72] and with lymph node involvement in laryngeal carcinomas [103]. In addition,
the methylation of MGMT was associated with poor survival and reduced disease-free sur‐
vival in OSCC [104] and increased recurrences rate and poor prognosis of HNSCC [105].
hMLH1 mutL homolog 1 is involved in the DNA repair process. The hMLH1 promoter meth‐
ylation occurred in high frequency of the majority of the early stage OSCC and in about half
of the late stage carcinomas [106], indicating its potential role in the tumor progression. Pro‐
moter methylation of hMLH1 gene is also a common event in HNSCC, and was correlated
with poor survival in HNSCC [107].
RARß Retinoic acid receptor beta is commonly methylated in HNSCC [59] and associated
with highly differentiated tumors, advanced tumor stage and the presence of lymph node
metastasis of nasopharyngeal carcinomas [78].
TIMP3 Tissue inhibitor of metalloproteinases 3 gene is involved in the inhibition of angio‐
genesis and tumor growth. Promoter methylation of TIMP3 predicts better outcome in
HNSCC treated by radiotherapy [91].
DCC Deleted in colorectal cancer, tumor suppressor gene highly methylated in HNSCC [108]
was correlated with mandibular invasion and poor survival in oral cancer [109].
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FHIT Fragile Histidine Triad gene is associated highly methylated in HNSCC [96], and asso‐
ciated with poor prognosis in early stage esophageal squamous cell carcinoma [110].
MINT1 and MINT 31, are the members of Methylated in tumor gene family, which methyla‐
tion was previously associated with invasiveness and poor survival in the OSCC [109].
A number of recent data suggests that promoter hypermethylation of specific genes does not
occur independently or randomly, but concurrently, which indicate that during the tumor
progression progressive accumulation of epigenetic alterations could occur. High degree of
methylation of multiple genes CpG island regions, associated with microsatellite instability
and hMLH1 gene hypermethylation, has been defined as a CpG island methylator pheno‐
type (CIMP) in colorectal cancer, and is characterized by a poor outcome [111]. It has been
suggested that a form of the CpG island methylator phenotype (CIMP) exists in other solid
tumors, including HNSCC [112]. As opposed of CIMP positive colorectal cancers In oral can‐
cer CIMP is characterized by less aggressive tumor biology [113],. The panel of tumor-relat‐
ed genes used to classify multiple methylation and CIMP differs substantially between
studies [12, 112, 113], which could likely affect the results of association with clinical param‐
eters and prognosis. Future extensive investigations are needed to establish a reliable set of
reference cancer-related genes whose methylation status should be examined in the specific
types of tumors. Further investigations are needed to better characterize the etiology of this
methylation phenotype as well as to determine if this phenotype has important prognostic
or clinical use.
3.3. DNA methylation in early detection of HNSCC
The detection of aberrant DNA hypermethylation emerged as a potential biomarker strategy
for early detection of various carcinomas. Since DNA methylation is an early event in tu‐
morigenesis of HNSCC, identification of methylation markers could provide great promise
for early detection and treatment in HNSCC [68]. As opposed to advanced HNSCC diagno‐
sis, early HNSCC detection increases survival to 80%. Therefore, early detection markers
may potentially serve as a predictive tool for diagnosis and recurrence of HNSCC. However,
even though such markers provide great promise for early detection, epigenetic biomarkers
have not yet been clinically implemented [114, 115].
Routine oral visual screening could significantly reduce oral cavity mortality [116]. Howev‐
er, oral cavity screening will not identify cancers deep in the pharynx or larynx which re‐
quires special instrumentation and examination. In addition, screening of HNSCC should
involve noninvasive detection of OSCC and HNSCC, such as detection in saliva and oral
rinses, or minimally invasive detection, such as blood and serum analysis. Saliva presents an
ideal means for HNSCC biomarker detection because of its proximity to the primary tumor
site, availability of exfoliated cancer cells, and ease of sampling [117, 118].
Soluble CD44 promoter gene hypermethylation detected in saliva samples has been indicat‐
ed as an early detection marker in HNSCC screening [119]. Recently, NID2 and HOXA9 pro‐
moter hypermethylation have been identified as biomarkers for prevention and early
detection in oral carcinoma tissues and saliva [120]. Hypermethylation of multiple tumor-
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related genes (RAR-β, DAPK, CDH1, p16 and RASSF1A) analyzed in combination could
serve as a biomarker for early diagnosis of esophageal squamous cell carcinoma [57]. More‐
over, these multiple tumor-related gene hypermethylation were associated with the increase
of DNMT3b expression in early stages of esophageal cancer [57].
The development methylation-specific polymerase chain reaction (PCR) techniques has re‐
sulted in the identification of methylated genes specific to HNSCC detected in tumor sam‐
ples [68], including DAPK [42], and RASSF1A [72].
Saliva and oral rinses could be ideal diagnostic and predictive biofluids for head and neck
cancer since they samples cells from the entire lesion and the entire oral cavity. The detec‐
tion of hypermethylated marker genes from oral rinse and saliva samples has a great poten‐
tial for the noninvasive detection of OSCC and HNSCC [118, 68, 121, 122, 123, 124]. DNA
hypermethylation of p16, MGMT, and DAPK in saliva showed aberrant methylation in 56%
of samples from HNSCC patients, and only in one of the 30 control subjects [68]. The aber‐
rant methylation of a combination of marker genes E-cadherin, transmembrane protein with
epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2), and MGMT, present
in oral rinses was used to detect OSCC with >90% sensitivity and specificity [124].
Using the approach of gene selection according to previous studies on promoter methyla‐
tion in HNSCC Carvalho et al. analyzed both saliva and serum in 211 HNSCC patients and
527 normal controls, and showed high specificity of promoter hypermethylation in HNSCC
patients compared with normal subjects (>90%); however, the sensitivity of this panel was
31.4% [118]. In another study with different approaches, genome-wide methylation array
analysis of 807 cancer-associated genes, was conducted on the matched preoperative saliva,
postoperative saliva, and oral cancer tissue, and compared to saliva of normal subjects. Mul‐
tiple potential diagnostic gene panels that consisted of 4 to 7 genes ranged in their sensitivi‐
ty from 62% to 77% and in their specificity from 83% to 100% [123], significantly higher than
previous studies of aberrant methylation detected in saliva in head and neck cancer patients
[121, 122, 118]. Using this approach, new genes could be discovered that can be used as a
reliable biomarker for the early detection of oral and head and neck cancer.
The KIF1A (Kinesin family member 1A) gene, that encodes a microtubule-dependent molec‐
ular motor protein involved in organelle transport and cell division, has recently been asso‐
ciated with aberrant DNA methylation in HNSCC [125]. EDNRB (Endothelin receptor type
B) is a G protein coupled receptor, which activates a phosphatidylinositol calcium second
messenger system, has previously been associated with nasopharyngeal carcinomas [126]
and HNSCC [125]. Promoter hypermethylation of KIF1A and EDNRB is a frequent event in
primary HNSCC, and these genes are preferentially methylated in salivary rinses from
HNSCC patients. KIF1A (97.8% specificity and 36.6% sensitivity) and EDNRB (93.2% specif‐
icity and 67.6% sensitivity) are highly sensitive markers that could potentially be used as bi‐
omarkers for HNSCC detection. In addition, combining the markers improves sensitivity
while maintains good specificity (93.1% specificity and 77.4% sensitivity) [125].
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3.4. Predictive significance of DNA methylation
Epigenetic alterations such as DNA methylation could be a marker of response to radio
and/or chemotherapy in the treatment of cancer. DNA methylation could play an important
role in the regulation of gene expression for genes involved in cell cycle and apoptosis, thus
affecting the chemosensitivity of cancers. Treatment of cancer cells with demethylating
agent could lead to re-expression of gene involved in the activation of the apoptotic process
and restore the sensitivity to the chemotherapy. Targeting the epigenetic mechanisms of
apoptosis related genes inactivation may increase the efficacy of chemotherapy in various
cancer types. Studies in vitro and in model systems certainly suggest that treatment with ep‐
ipgenetic agents can reverse drug resistance.
The best known example of DNA promoter hypermethylation and response to chemothera‐
py is MGMT promoter methylation in glioma patients treated with alkylating agents [127].
The expression of DNA repair gene MGMT, which removes alkyl groups added to guanine
in DNA, is controlled by its promoter methylation. A cell that expresses a low amount of
MGMT is known to be more sensitive to the antiproliferative effects of alkylating agents. It
has been shown that hypermethylation of MGMT is the predictor of good response to temo‐
zolomide therapy in gliomas [128], to carmustine therapy in gliomas [127], and to cyclo‐
phosphamide therapy in diffuse B cell lymphoma [129]. Acquired hypermethylation of
DNA mismatch repair gene hMLH1 (detectable in peripheral blood) during carboplatinum/
taxane therapy of ovarian cancer predicts poorer outcome [130]. In addition, WRN gene pro‐
moter hypermethylation was associated with hypersensitivity to topoisomerase inhibitor iri‐
notecan in primary colon cancer [131].
It has been shown that DNA methylation could have the predictive significance in OSCC
and HNSCC. Hypermethylation of MGMT was the predictor of good response to temozolo‐
mide therapy in oral squamous cell carcinoma [105]. GPx3 promoter hypermethylation was
associated with tumorigenesis and chemotherapy response in HNSCC [132]. A correlation
between methylation of mitotic checkpoint gene CHFR (checkpoint with ring finger) and
sensitivity to microtubule inhibitors (docetaxel or paclitaxel) was observed in OSCC cells
[133]. Downregulation of SMG-1 (suppressor with morphogenetic effect on genitalia) due to
promoter hypermethylation in HPV-Positive HNSCC resulted in increased radiation sensi‐
tivity and correlated with improved survival, whereas SMG-1 overexpression protected
HPV-positive tumor cells from irradiation [134]. DNA methylation could be a regulatory
mechanism for chemosensitivity to 5-fluorouracil and cisplatin by zebularine, a novel DNA
methyltransferase inhibitor, in oral squamous cell carcinomas [135]. It has been shown that
zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB path‐
way in human oral carcinoma cells [136].
Radiotherapy is the standard adjuvant treatment for OSCC and the Ras/PI3K/AKT pathway
plays an important role in OSCC radioresistance. A combination of RASSF1A, RASSF2A,
and HIN-1 methylation was found to be significantly associated with poor disease-free sur‐
vival in patients treated with radiotherapy after surgery but not in patients treated with sur‐
gery alone [79].
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TGF-β signaling has been found to be disrupted in HNSCC progression [137], thus this path‐
way has been targeted for therapy [138]. Downregulation of disabled homolog 2 (DAB2)
gene expression via promoter DNA methylation frequently occurs in HNSCC and acts as an
independent predictor of metastasis and poor prognosis [139]. Epigenetic downregulation of
DAB2 switches TGF-β from a tumor suppressor to a tumor promoter, suggest a way to strat‐
ify patients with advanced SCC who may benefit from anti-TGF-β therapies [139].
Although methylation of certain genes appears to influence the sensitivity to chemothera‐
peutic drugs, the majority of studies were performed on cell line models, or a small number
of subjects. In addition, combination therapies of epigenetic agents and standard chemother‐
apy/radiotherapy have to be carefully investigated due to potential harmful effects in the
clinical application of DNMT inhibitors. Epigenetic profile in predicting the chemosensitivi‐
ty of individual cancers would contribute to personalized therapy [140]. Studies of pharma‐
coepigenomics will require large-scale analyses and genome-wide methylation analyses
using microarrays and next-generation sequencers, necessary to confirm the usage of epige‐
netic changes in predicting responses to chemotherapeutic drugs.
3.5. Epigenetic therapy of HNSCC
Unlike mutations, epigenetic changes are reversible, which provides large possibilities of ep‐
igenetic therapy [141]. Demethylating agents that inhibit DNA methyltransferases DNMTs,
could have a utility to effectively activate expression of previously epigenetically silenced
genes. 5-azanucleosides, nucleoside analogs that inhibit DNMTs, with consequent hypome‐
thylation of DNA, have long been known to have DNA demethylating activities, but are too
toxic for clinical use [141]. However, recent studies have shown that therapeutic efficacy
could be achieved at low drug doses [142 -4]. 5-Azacytidine, a cytosine analog treatment has
been tested in multiple cancer cell lines and are shown to reexpress methylated genes in
myelodysplastic syndromes (MDS) [142, 143]. Low doses were used in a large trial in pa‐
tients with MDS, and showed an increase in the time of conversion of MDS to leukemia, and
increased overall survival [144].
5-Azacytidine application resulted in partial demethylation of the MGMT and RASSF1A tu‐
mor suppressor genes and reduced proliferation of the tumor cells suggesting further inves‐
tigation of 5-azacytidine for HNSCC treatment [145]. Methylation status and expression of
HIC1, a potential tumor suppressor gene, was restored after demethylation treatment of
HNSCC cell lines with 5-azacytidine [146].
Epigenetic therapy in monotherapy could reactivate tumor suppressor genes or in combina‐
tion therapy may enhance the anti-proliferative effect of standard chemotherapy, such as
cisplatin, 5-fluorouracil, etc. The low dose of a novel DNA methyltransferase inhibitor, ze‐
bularine may sensitize oral cancer cells to cisplatin, an important characteristic of solid can‐
cer treatment. DNA methylation could be a regulatory mechanism for dihydropyrimidine
dehydrogenase (DPD), known to be a principal factor in 5-fluorouracil (5-FU) resistance and
that DPD activated by zebularine in OSCC could be an inhibiting factor in the response to
apoptosis induced by 5-FU [135].
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The epidermal growth factor receptor (EGFR) has been extensively investigated and validat‐
ed as a therapeutic target in lung, colorectal, pancreatic, and head and neck cancers. Howev‐
er, patients with wild type EGFR obtain little sustained benefit from anti-EGFR
monotherapy Broad restoration of tumor suppressor function by demethylation could en‐
hance the anti-proliferative and pro-apoptotic effect of EGFR blockade in solid malignancy.
Re-expression of p15, p21, or p27, cell cycle inhibitors downstream of EGFR, or PTEN, a
PI3K/Akt inhibitory protein, may have particular synergy with anti-EGFR therapy. Recent
phase I study evaluated the combination of anti-EGFR erlotinib and 5-azacytidine in solid
carcinomas showed the beneficial clinical effect in lung and head and neck cancers [147]. Ef‐
ficacy of erlotinib could be enhanced by concurrent hypomethylating therapy with 5-azacy‐
tidine, secondary to re-expression of tumor suppressors interacting with the EGFR signaling
cascade. In recent study of resistance to anti-EGFR therapy agents, promoter methylation of
commonly methylated genes was investigated in two parental non-small cell lung cancer
(NSCLC) and HNSCC cell lines and their resistant derivatives to either erlotinib or cetuxi‐
mab [148]. It was found that DAPK gene promoter was hypermethylated in drug-resistant
derivatives generated from both parental cell lines. Restoration of DAPK into the resistant
NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab
[148], thus indicating that DAPK promoter methylation could be a potential biomarker of
drug response.
These results demonstrate that DNA methylation could play an important role in both che‐
motherapy and radiotherapy resistance, and that gene silencing through promoter methyla‐
tion is one of the key mechanisms of developed resistance to anti-EGFR therapeutic agents.
Epigenetic therapy could be a novel treatment to overcome chemo- and/or radiotherapy re‐
sistance and to improve the benefits of current therapies.
3.6. DNA methylation in HNSCC and etiological factors
Epidemiological studies have reported the association of DNA methylation status in HNSCC
with exposure to environmental factors, including tobacco smoke, alcohol intake, genotoxic
betel quid consumption, HPV infection, diet and environmental pollutants.
Recent studies have shown a correlation between tobacco and/or alcohol use and hyperme‐
thylation of tumor related genes. DNA global hypomethylation was associated with alcohol
consumption [149]. p16 methylation has been correlated with alcohol use and smoking [72].
Promoter methylation of p16 was previously correlated with alcohol intake [150], while
RASSF1A methylation was associated with tobacco use in HNSCC [72]. Smoking and drink‐
ing was associated with p15 promoter methylation in the upper aerodigestive tract of
healthy individuals and HNSCC patients [151]. Promoter methylation of SFRP1 occurred
more often in both heavy and light drinkers compared to nondrinkers in head and neck squ‐
amous cell carcinoma [152]. Significant association of tumor-associated genes hypermethyla‐
tion with alcohol use was observed in HNSCC [153].
Recent studies are indicating that increased fruit and vegetable consumption are associated
with reduced head and neck cancer risk [28]. There is a growing body of evidence that bio‐
active food components, such as isothiocyanates from cruciferous vegetables (cauliflower,
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cabbage, and broccoli), diallyl sulfide, an organosulphur compound from garlic, isoflavone,
phytosterole, folate, selenium, vitamin E, flavonoids might reduce cancer risk through epi‐
genetic mechanisms. The chemoprevention of cancer by natural compounds could be a
promising approach with less side effects and toxicity. Main polyphenols with the proper‐
ties of DNMT inhibition are tea polyphenols, soy isoflavones, organosulphur compounds
from garlic, and isothiocyanates from cruciferous vegetables. Dietary folate intake was asso‐
ciated with p16 promoter methylation in head and neck squamous cell carcinoma [154]. Epi‐
gallocatechin-3-gallate (EGCG), the major polyphenol in green tea, is believed to be a key
active ingredient with anti-cancer properties. EGCG is methylated by catechol-O-methyl‐
transferase and inhibits DNA methyltransferase (DNMT), thus reversing the hypermethyla‐
tion and inducing the re-expression of the silenced genes [141].
EGCG has been reported to reverse hypermethylation and reactivate several tumor suppres‐
sor genes in human esophageal squamous cell carcinoma cell lines [155]. The reversion-in‐
ducing cysteine-rich protein with Kazal motifs (RECK), a novel matrix metalloproteinases
(MMP) inhibitor, is involved in the inhibition of tumor angiogenesis, invasion, and metasta‐
sis. EGCG treatment enhanced RECK expression by reversal of hypermethylation of RECK
promoter and inhibiting MMP activities and invasion in OSCC cell lines [156]. Genistein, soy
dietary isoflavone, reversed DNA hypermethylation and reactivated RARβ, p16, and MGMT
in esophageal cancer cells [157]. However, the findings of association of diet and epigenetic
modifications in the head and cancer and other carcinomas are still confounding.
4. Conclusions
Head and neck squamous cell carcinoma (HNSCC) is one of the most common and highly
aggressive malignancies worldwide, despite the significant efforts committed in the last dec‐
ades in its detection, prevention and treatment. Therefore, early detection and better disease
prediction via genetic and epigenetic biomarkers is crucial. However, very few reliable
markers are currently known. Recent studies provide strong evidence that DNA methyla‐
tion could have an important role in head and neck cancer. The detection of promoter meth‐
ylation status may be a useful molecular marker for early detection of HNSCC from tissue,
saliva, and serum samples and in real time analysis of margins during surgery. In addition,
the creation of methylation gene panels could be useful for HNSCC screening in the timely
inclusion of treatment and thorough surveillance during follow-up period. Unlike genetic
changes, epigenetic modifications are heritable and potentially reversible, thus providing
the potential for therapy. Frequent DNA methylation detected in HNSCC and association
with tumor progression and survival indicates that DNA methylation plays an important
role in head and neck carcinogenesis and may be a useful diagnostic marker and a potential
therapeutic target for HNSCC.
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